曲妥珠-话题@MedSci

#曲妥珠#

132篇内容 | 3543人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1648189, encodeId=dfab16481898a, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, objectType=article, longId=217767, objectId=989c21e7670d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989c21e7670d, replyNumber=0, likeNumber=73, createdTime=2022-09-01, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989c21e7670d, moduleTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989c21e7670d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648176, encodeId=fee316481e640, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：曲妥珠单抗联合帕妥珠单抗固定剂量皮下注射治疗HER2阳性乳腺癌的疗效可媲美静脉用药！, objectType=article, longId=204808, objectId=a44820480803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44820480803, replyNumber=0, likeNumber=89, createdTime=2021-06-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44820480803, moduleTitle=Lancet Oncol：曲妥珠单抗联合帕妥珠单抗固定剂量皮下注射治疗HER2阳性乳腺癌的疗效可媲美静脉用药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a44820480803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648190, encodeId=4933164819096, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, objectType=article, longId=219118, objectId=d4b221911890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4b221911890, replyNumber=0, likeNumber=0, createdTime=2022-02-26, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4b221911890, moduleTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4b221911890)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648182, encodeId=934e16481827f, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究, objectType=article, longId=214418, objectId=1d9b21441830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9b21441830, replyNumber=0, likeNumber=64, createdTime=2021-11-04, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9b21441830, moduleTitle=Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9b21441830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648175, encodeId=20e516481e56a, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, objectType=article, longId=204512, objectId=cc0e204512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc0e204512c6, replyNumber=0, likeNumber=63, createdTime=2021-11-07, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc0e204512c6, moduleTitle=CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc0e204512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648183, encodeId=cf8f1648183ed, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=89, createdTime=2021-12-01, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648173, encodeId=364e16481e38c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的, objectType=article, longId=203354, objectId=409a203354b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=409a203354b2, replyNumber=0, likeNumber=89, createdTime=2021-10-16, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=409a203354b2, moduleTitle=Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=409a203354b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648181, encodeId=a21016481819e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, objectType=article, longId=214034, objectId=f1b7214034fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1b7214034fe, replyNumber=0, likeNumber=83, createdTime=2022-03-21, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1b7214034fe, moduleTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1b7214034fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648178, encodeId=c82016481e8ad, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, objectType=article, longId=210899, objectId=70f82108996e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70f82108996e, replyNumber=0, likeNumber=68, createdTime=2022-02-27, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70f82108996e, moduleTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70f82108996e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648168, encodeId=4a6c1648168fe, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=复宏汉霖曲妥珠单抗生物类似物获欧盟批准上市, objectType=article, longId=198341, objectId=5c4c198341c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4c198341c7, replyNumber=0, likeNumber=94, createdTime=2020-12-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4c198341c7, moduleTitle=复宏汉霖曲妥珠单抗生物类似物获欧盟批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4c198341c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648179, encodeId=1c7f16481e914, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, objectType=article, longId=211004, objectId=c2ae2110047c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ae2110047c, replyNumber=0, likeNumber=103, createdTime=2021-11-17, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ae2110047c, moduleTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ae2110047c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648177, encodeId=249d16481e70c, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟, objectType=article, longId=210360, objectId=43fb210360da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43fb210360da, replyNumber=0, likeNumber=99, createdTime=2021-09-08, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43fb210360da, moduleTitle=罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43fb210360da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648171, encodeId=7b3116481e1d5, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：帕博西利联合曲妥珠单抗治疗HER2+晚期乳腺癌的疗效, objectType=article, longId=200794, objectId=45ff200e942d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45ff200e942d, replyNumber=0, likeNumber=88, createdTime=2021-08-13, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45ff200e942d, moduleTitle=Clin Cancer Res：帕博西利联合曲妥珠单抗治疗HER2+晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45ff200e942d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648166, encodeId=68c01648166ea, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, objectType=article, longId=196865, objectId=2899196865f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2899196865f2, replyNumber=0, likeNumber=92, createdTime=2020-11-17, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2899196865f2, moduleTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2899196865f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648165, encodeId=76ae164816502, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=J Clin Oncol：辅助紫杉醇和曲妥珠单抗试验治疗结节阴性、人表皮生长因子受体2阳性乳腺癌的七年随访分析, objectType=article, longId=195901, objectId=b90719590192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b90719590192, replyNumber=0, likeNumber=92, createdTime=2020-11-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b90719590192, moduleTitle=J Clin Oncol：辅助紫杉醇和曲妥珠单抗试验治疗结节阴性、人表皮生长因子受体2阳性乳腺癌的七年随访分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b90719590192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648174, encodeId=7d6116481e425, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, objectType=article, longId=203556, objectId=4991203556ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4991203556ab, replyNumber=0, likeNumber=80, createdTime=2021-01-06, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4991203556ab, moduleTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4991203556ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648163, encodeId=8f1c16481630b, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=ASCO 2020 | 无处不在的曲妥珠单抗, objectType=article, longId=195360, objectId=5fa919536006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fa919536006, replyNumber=0, likeNumber=76, createdTime=2021-04-06, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fa919536006, moduleTitle=ASCO 2020 | 无处不在的曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fa919536006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648161, encodeId=82d81648161aa, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, objectType=article, longId=194124, objectId=c8f2194124ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8f2194124ca, replyNumber=0, likeNumber=75, createdTime=2020-10-09, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8f2194124ca, moduleTitle=英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8f2194124ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648159, encodeId=8327164815903, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后, objectType=article, longId=190229, objectId=fd1819022915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1819022915, replyNumber=0, likeNumber=0, createdTime=2021-01-02, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1819022915, moduleTitle=Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd1819022915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1648172, encodeId=60b116481e2ab, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, objectTitle=国产曲妥珠单抗纳入上海医保，个人自付670元/瓶, objectType=article, longId=200839, objectId=da2a200839bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da2a200839bf, replyNumber=0, likeNumber=89, createdTime=2020-12-08, rootId=0, userName=linlin2320, userId=a67b23554000, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da2a200839bf, moduleTitle=国产曲妥珠单抗纳入上海医保，个人自付670元/瓶, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da2a200839bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

曲妥珠

2020-05-29

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性

2022-09-01

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：曲妥珠单抗联合帕妥珠单抗固定剂量皮下注射治疗HER2阳性乳腺癌的疗效可媲美静脉用药！

2021-06-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效

2022-02-26

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Eur J Cancer：曲妥珠单抗-拉帕替尼新辅助治疗HER2+早期乳腺癌患者的疗效：来自CHER-Lob研究

2021-11-04

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

CHMP推荐曲妥珠单抗Deruxtecan治疗HER2阳性转移性乳腺癌

2021-11-07

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2021-12-01

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Gastric Cancer：无论之前是否使用过曲妥珠单抗，nivolumab作为晚期G/GEJ癌患者的三线或后线治疗都是有效和安全的

2021-10-16

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析

2022-03-21

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性

2022-02-27

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

复宏汉霖曲妥珠单抗生物类似物获欧盟批准上市

2020-12-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后

2021-11-17

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟

2021-09-08

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：帕博西利联合曲妥珠单抗治疗HER2+晚期乳腺癌的疗效

2021-08-13

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗

2020-11-17

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

J Clin Oncol：辅助紫杉醇和曲妥珠单抗试验治疗结节阴性、人表皮生长因子受体2阳性乳腺癌的七年随访分析

2020-11-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌

2021-01-06

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

ASCO 2020 | 无处不在的曲妥珠单抗

2021-04-06

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

英国NICE支持罗氏的ADC药物Kadcyla恩美曲妥珠单抗，治疗HER2阳性的早期乳腺癌

2020-10-09

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

Lancet oncol：帕妥珠单抗+曲妥珠单抗+多西他赛治疗HER2+转移性乳腺癌的8年预后

2021-01-02

linlin2320 (审核中...)

前往app查看评论内容

#曲妥珠#

国产曲妥珠单抗纳入上海医保，个人自付670元/瓶

2020-12-08

科室
- - 订阅+
  - 更多科室
工具
服务